Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Dithranol: An Insight into its Novel Delivery Cargos for Psoriasis Management

Author(s): Varsha Kadian, Sunil Kumar, Komal Saini, Vandita Kakkar and Rekha Rao*

Volume 12, Issue 2, 2020

Page: [82 - 96] Pages: 15

DOI: 10.2174/2589977512666200525154954

Price: $65

conference banner
Abstract

Objective: Dithranol (DTH) is a well-known moiety that has long been used promisingly to impede and treat skin disorders, particularly psoriasis. Nowadays, a rekindled interest in the use of DTH for this disorder has been observed. Side effects associated with conventional topical formulations of this moiety have aroused the interest of the scientific community in investigating novel cargos of DTH for psoriasis management.

Results: Previous research has evidenced the anti-inflammatory and anti-proliferating potential of DTH. Numerous studies have indicated that DTH inhibits polymorphonuclear (PMN) leucocyte, modulates epidermal cell receptors and promotes anti-psoriatic action. However, some deterrent factors like poor solubility, stability, toxicity, staining and skin irritation hamper its use as a potential therapeutic agent. With the adoption of novel drug delivery technologies, the above mentioned inherent limitations of DTH have been compensated to reestablish this drug moiety.

Conclusion: This article reviews novel drug delivery aspects, safety concerns, clinical evidence, current status, and future opportunities of DTH in the management of psoriasis. Further, it will update researchers on this promising drug moiety, which is free from systemic adverse responses in comparison to other therapeutic molecules like steroids, for psoriasis treatment.

Keywords: Dithranol, anti-psoriatic potential, delivery systems, safety concerns, pharmacokinetics, clinical aspects.

« Previous
Graphical Abstract

[1]
Ashton RE, Andre P, Lowe NJ, Whitefield M. Anthralin: Historical and current perspectives. JAAD 1983; 9(2): 173-92.
[http://dx.doi.org/10.1016/S0190-9622(83)70125-8] [PMID: 6309924]
[2]
Fathalla D, Youssef EMK, Soliman GM. Liposomal and ethosomal gels for the topical delivery of anthralin: preparation, comparative evaluation and clinical assessment in psoriatic patients. Pharmaceutics 2020; 12(5): 446.
[http://dx.doi.org/10.3390/pharmaceutics12050446] [PMID: 32403379]
[3]
Sehgal VN, Verma P, Khurana A. Anthralin/dithranol in dermatology. Int J Dermatol 2014 Oct; 53(10): e449-60.
[http://dx.doi.org/10.1111/j.1365-4632.2012.05611.x ] [PMID: 25208745]
[4]
Kemény L, Ruzicka T, Braun-Falco O. Dithranol: A review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol Physiol 1990; 3(1): 1-20.
[http://dx.doi.org/10.1159/000210836] [PMID: 2202336]
[5]
Agrawal U, Mehra NK, Gupta U, Jain NK. Hyperbranched dendritic nano-carriers for topical delivery of dithranol. J Drug Target 2013; 21(5): 497-506.
[http://dx.doi.org/10.3109/1061186X.2013.771778 ] [PMID: 23594093]
[6]
Liu P, Lu Y, Recker RR, Deng HW, Dvornyk V. ALOX12 gene is associated with the onset of natural menopause in white women. Menopause 2010; 17(1): 152-6. Available from: https://www.mayoclinic.org/drugs-supplements/ anthralin-topical-route/description/drg-20061896
[7]
Su Y-H, Fang J-Y. Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin Drug Deliv 2008; 5(2): 235-49.
[http://dx.doi.org/10.1517/17425247.5.2.235] [PMID: 18248321]
[8]
Van Scott EJ, Ruey JY. inventors; Scott Eugene J Van, Yu Ruey Y. assignee Dithranol compositions stabilized with alpha hydroxyacids United States patent US 4,287,214, 1981 Sep;
[9]
Ruey JY, Van Scott EJ. inventors; Yu Ruey J, Scott Eugene J Van. assignee Therapeutic compositions and vehicles for topical pharmaceuticals United States patent US 4,316,902, 1982 Feb;
[10]
Van Scott EJ, Ruey JY. inventors; Scott Eugene J Van, Yu Ruey J. assignee Stable dithranol compositions in anhydrous vehicles United States patent US 4,367,224, 1983 Jan;
[11]
Grollier JF, Rosenbaum G, Allec J, Shroot B. inventors; Loreal SA. assignee Composition in the form of a shampoo based on anthralin United States patent US 4,513,011, 1985 Apr;
[12]
Grollier JF, Rosenbaum G, Allec J, Shroot B. inventors; L'oreal SA. assignee Anhydrous composition, stable to oxidation, based on anthralin or one of its derivatives, in a carrier consisting of a fatty acid alkyl ester and a thickener, and its use in the treatment of skin diseases United States patent US 4,495,203, 1985 Jan;
[13]
Yarrow H, Whitefield M. inventors; Drythanol Ltd. assignee Dithranol compositions for topical applications United States patent US 4,203,969, 1980 May 20;
[14]
Rosenberg EW, Glenn TM, Skinner Jr RB, Noah PW. inventors; Panda Pharmaceuticals LLC, University of Tennessee Research Foundation,. assignee Composition and method for treatment of psoriasis United States patent US 5,990,100, 1999 Nov 23;
[15]
Wang JC. inventors; Bristol Myers Squibb Co.. assignee Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant United States patent US 5,034,420, 1991 Jul 23;
[16]
Whitefield M. inventors; Drythanol Ltd.. assignee Dithranol composition containing no oily ingredients United States patent US 5,061,486, 1991 Oct;
[17]
Schneider J, Wohlrab W, Neubert R, Huschka C, Koegst D, Fries G. inventors; esparma GmbH.. assignee Pharmaceutical preparation containing dithranol United States patent US 6,413,950, 2002 Jul;
[18]
Rosenberg EW, Glenn TM, Skinner Jr RB, Noah PW. inventors; Panda Pharmaceuticals LLC., University of Tennessee Research Foundation. assignee Composition and method for treatment of psoriasis United States patent US 5,990,100, 1999 Nov;
[19]
Evans FJ, Taylor EJ. Chalcone plant extracts for use in therapy EP0998939A12000. Available from: https://patents.google.com/ patent/EP0998939A1/en
[20]
Van Scott EJ, Ruey JY. inventors; Method for topical treatment of anthralin-responsive dermatological disorders United States patent US 6,403,123, 2002 Jun 11;
[21]
Gidwani SK, Singnurkar PS. inventors; USV Pvt Ltd.. assignee Composition for delivery of dithranol United States patent application US 10/371,295, 2003 Nov;
[22]
Katare OP, Agarwal R, Kumar B. inventors; Lifecare Innovations Pvt Ltd. assignee Novel Inter and Intra Multilamellar Vesicular Composition United States patent application US 11/909,350, 2008 Jul 17;
[23]
Thoma K, Holzmann C. Photostability of dithranol. Eur J Pharm Biopharm 1998; 46(2): 201-8.
[http://dx.doi.org/10.1016/S0939-6411(98)00024-1] [PMID: 9795061]
[24]
Estanqueiro M, Conceição J, Amaral MH, Lobo JMS. Use of solid dispersions to increase stability of dithranol in topical formulations. Braz J Pharm Sci 2014; 50(3): 583-90.
[http://dx.doi.org/10.1590/S1984-82502014000300018]
[25]
Saraswat A, Agarwal R, Kaur I, Katare OP, Kumar B. Fabric-staining properties and washability of a novel liposomal dithranol formulation. J Dermatolog Treat 2002; 13(3): 119-22.
[http://dx.doi.org/10.1080/09546630260199479] [PMID: 12227874]
[26]
Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001; 228(1-2): 43-52.
[http://dx.doi.org/10.1016/S0378-5173(01)00810-9 ] [PMID: 11576767]
[27]
Guenther U, Smirnova I, Neubert RHH. Hydrophilic silica aerogels as dermal drug delivery systems--dithranol as a model drug. Eur J Pharm Biopharm 2008; 69(3): 935-42.
[http://dx.doi.org/10.1016/j.ejpb.2008.02.003] [PMID: 18423994]
[28]
Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare OP. Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous absorption studies. J Microencapsul 2011; 28(3): 190-9.
[http://dx.doi.org/10.3109/02652048.2010.546435] [PMID: 21395406]
[29]
Gambhire MS, Bhalekar MR, Gambhire VM. Statistical optimization of dithranol-loaded solid lipid nanoparticles using factorial design. Braz J Pharm Sci 2011; 47(3): 503-11.
[http://dx.doi.org/10.1590/S1984-82502011000300008]
[30]
Raza K, Katare OP, Setia A, Bhatia A, Singh B. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J Microencapsul 2013; 30(3): 225-36.
[http://dx.doi.org/10.3109/02652048.2012.717115] [PMID: 23088318]
[31]
Savian AL, Rodrigues D, Weber J. Dithranol-loaded lipid-core nanocapsules improve the photostability and reduce the in vitro irritation potential of this drug. Mater Sci Eng C 2015; 46: 69-76.
[http://dx.doi.org/10.1016/j.msec.2014.10.011] [PMID: 25491961]
[32]
World Health Organization. Global Report on Psoriasis. World Health Organization 2016.
[33]
Suresh PK, Singh P, Saraf S. Novel topical drug carriers as a tool for treatment of psoriasis: progress and advances. Afr J Pharm Pharmacol 2013; 7(5): 138-47.
[http://dx.doi.org/10.5897/AJPPX12.001]
[34]
Langan SM, Seminara NM, Shin DB. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132(3): 556-62.
[http://dx.doi.org/10.1038/jid.2011.365] [PMID: 22113483]
[35]
Gustav M.M.D. Dithranol. Clin Dermatol 1997; 15(5): 723-37.
[http://dx.doi.org/10.1016/S0738-081X(97)00019-9] [PMID: 9313971]
[36]
Mahrle G, Bonnekoh B, Wevers A, Hegemann L. Anthralin: how does it act and are there more favourable derivatives? Acta Derm Venereol Suppl (Stockh) 1994; 186: 83-4.
[PMID: 8073848]
[37]
Kemény L, Gross E, Arenberger P, Ruzicka T. Dithranol-induced down-regulation of 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] receptors in a human epidermal cell line. Arch Dermatol Res 1991; 283(5): 333-6.
[http://dx.doi.org/10.1007/BF00376623] [PMID: 1656897]
[38]
Schröder J, Christophers E. Identification of C5ades arg and an anionic neutrophil-activating peptide (anap) in psoriatic scales. Jour of Inv Dermatol 1986; 87(1): 53-8.
[http://dx.doi.org/10.1111/1523-1747.ep12523566] [PMID: 3014008]
[39]
Tucker WF, MacNeil S, Dawson RA, Tomlinson S, Bleehen SS. An investigation of the ability of antipsoriatic drugs to inhibit calmodulin activity: a possible mode of action of dithranol (anthralin). J Invest Dermatol 1986; 87(2): 232-5.
[http://dx.doi.org/10.1111/1523-1747.ep12696613] [PMID: 3016102]
[40]
Müller K. Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. Biochem Pharmacol 1997; 53(9): 1215-21.
[http://dx.doi.org/10.1016/S0006-2952(96)00732-0] [PMID: 9214681]
[41]
Majid I, Keen A. Management of alopecia areata: an update. Br J Med Pract 2012; 5(3)
[42]
Carlotti ME, Sapino S, Peira E, Gallarate M, Ugazio E. On the photodegradation of dithranol in different topical formulations: use of SLN to increase the stability of the drug. J Dispers Sci Technol 2009; 30(10): 1517-24.
[http://dx.doi.org/10.1080/01932690903123726]
[43]
Soliman GM, Osman SK, Hamdan AM. Preparation and evaluation of anthralin biodegradable nanoparticles as a potential delivery system for the treatment of psoriasis. Int J Pharm Pharm Sci 2015; 7(12): 36-40.
[44]
Tripathi PK, Gorain B, Choudhury H, Srivastava A, Kesharwani P. Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon 2019; 5(3)e01343
[http://dx.doi.org/10.1016/j.heliyon.2019.e01343] [PMID: 30957038]
[45]
Sathe P, Saka R, Kommineni N, Raza K, Khan W. Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model. Drug Dev Ind Pharm 2019; 45(5): 826-38.
[http://dx.doi.org/10.1080/03639045.2019.1576722 ] [PMID: 30764674]
[46]
Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971; 60(9): 1281-302.
[http://dx.doi.org/10.1002/jps.2600600902] [PMID: 4935981]
[47]
Fusenig NE, Capes-Davis A, Bianchini F, Sundell S, Lichter P. The need for a worldwide consensus for cell line authentication: Experience implementing a mandatory requirement at the international journal of cancer. PLoS Biol 2017; 15(4)e2001438
[http://dx.doi.org/10.1371/journal.pbio.2001438] [PMID: 28414712]
[48]
Remitz A. kariniemi A, lehtonen E, nordling S. Inhibition of proliferation of HeLa cells by dithranol (anthralin) and 10-butyryl dithranol (butantrone). Br J Dermatol 1989; 120(4): 525-31.
[http://dx.doi.org/10.1111/j.1365-2133.1989.tb01326.x ] [PMID: 2730843]
[49]
Bonnekoh B, Farkas B, Geisel J, Mahrle G. Lactate dehydrogenase release as an indicator of dithranol-induced membrane injury in cultured human keratinocytes. A time profile study. Arch Dermatol Res 1990; 282(5): 325-9.
[http://dx.doi.org/10.1007/BF00375727] [PMID: 2221984]
[50]
Ockenfels HM, Nussbaum G, Schultewolter T, et al. FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. Arch Dermatol Res 1995; 287(3-4): 304-9.
[http://dx.doi.org/10.1007/BF01105083] [PMID: 7541191]
[51]
Mrowietz U, Jessat H, Schwarz A, Schwarz T. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol 1997; 136(4): 542-7.
[http://dx.doi.org/10.1111/j.1365-2133.1997.tb02138.x ] [PMID: 9155955]
[52]
Farkas A, Kemény L, Szöny BJ, et al. Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Inflamm Res 2001; 50(1): 44-9.
[http://dx.doi.org/10.1007/s000110050723] [PMID: 11235021]
[53]
McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J 2005; 19(8): 1012-4.
[http://dx.doi.org/10.1096/fj.04-2664fje] [PMID: 15802490]
[54]
Tencomnao T, Ronpirin C, Prasansuklab A, Poovorawan Y. Decreased EGFR mRNA expression in response to antipsoriatic drug dithranol in vitro. Afr J Biotechnol 2009; 8(14)
[55]
Ronpirin C, Tencomnao T. Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro. Genet Mol Res 2012; 11(1): 412-20.
[http://dx.doi.org/10.4238/2012.February.17.3] [PMID: 22370944]
[56]
Ronpirin C, Tencomnao T. Dithranol downregulates expression of Id1 mRNA in human keratinocytes in vitro. Genet Mol Res 2012; 11(3): 3290-7.
[http://dx.doi.org/10.4238/2012.September.12.12] [PMID: 23079823]
[57]
George SE, Anderson RJ, Haswell M, Groundwater PW. An investigation of the effects of dithranol-induced apoptosis in a human keratinocyte cell line. J Pharm Pharmacol 2013; 65(4): 552-60.
[http://dx.doi.org/10.1111/jphp.12019] [PMID: 23488784]
[58]
Hollywood KA, Winder CL, Dunn WB. Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. Mol Biosyst 2015; 11(8): 2198-209.
[http://dx.doi.org/10.1039/C4MB00739E] [PMID: 26018604]
[59]
Khalil H, Loukili N, Regamey A, Cuesta-Marban A, Santori E, Huber M, et al. The caspase-3-p120-RasGAP module generates a NF- B repressor in response to cellular stress. J Cell Sci 2015; 128(18): 3502-13.
[http://dx.doi.org/10.1242/jcs.174409] [PMID: 26224876]
[60]
Richardson A, Muir L, Mousdell S, Sexton D, Jones S, Howl J, et al. Modulation of mitochondrial activity in HaCaT keratinocytes by the cell penetrating peptide Z-Gly-RGD(DPhe)-mitoparan. BMC Res Notes 2018; 11(1): 82.
[http://dx.doi.org/10.1186/s13104-018-3192-1] [PMID: 29378648]
[61]
Singh SK, Chouhan HS, Sahu AN, Narayan G. Assessment of in vitro antipsoriatic activity of selected Indian medicinal plants. Pharm Biol 2015; 53(9): 1295-301.
[http://dx.doi.org/10.3109/13880209.2014.976713] [PMID: 25856701]
[62]
Tse W-P, Che C-T, Liu K, Lin Z-X. Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J Ethnopharmacol 2006; 108(1): 133-41.
[http://dx.doi.org/10.1016/j.jep.2006.04.023] [PMID: 16730935]
[63]
Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 2018; 9(1): 15-32.
[http://dx.doi.org/10.1007/s13238-017-0408-4] [PMID: 28421387]
[64]
Thotakura N, Kumar P, Wadhwa S, Raza K, Katare P. Dermatokinetics as an important tool to assess the bioavailability of drugs by topical nanocarriers. Curr Drug Metab 2017; 18(5): 404-11.
[http://dx.doi.org/10.2174/1389200218666170306104042] [PMID: 28266274]
[65]
Schaefer H, Schalla W, Shroot B. Pharmacology and kinetics of anthralin. Psoriasis N Y Grune Strat Inc. 1982; pp. 111-8.
[66]
Wang JC, Patel BG, Ehmann CW, Lowe N. The release and percutaneous permeation of anthralin products, using clinically involved and uninvolved psoriatic skin. J Am Acad Dermatol 1987; 16(4): 812-21.
[http://dx.doi.org/10.1016/S0190-9622(87)70106-6] [PMID: 3571544]
[67]
Snater E, Janssen EA, van der Valk PG, van de Kerkhof PC. Transepidermal water vapour loss is not increased during and following dithranol irritation. Br J Dermatol 1995 Jun; 132(6): 908-12.
[http://dx.doi.org/10.1111/j.1365-2133.1995.tb16947.x] [PMID: 7662568]
[68]
Wester RC, Noonan PK. Relevance of animal models for percutaneous absorption. Int J Pharm 1980; 7(2): 99-110.
[http://dx.doi.org/10.1016/0378-5173(80)90054-X]
[69]
Gay MW, Moore WJ, Morgan JM, Montes LF. Anthra toxicity. Arch Dermatol 1972; 105(2): 213-5.
[http://dx.doi.org/10.1001/archderm.1972.01620050027004] [PMID: 5060864]
[70]
Goodfield MJ, Hull SM, Cunliffe WJ. The systemic effect of dithranol treatment in psoriasis. Acta Derm Venereol 1994; 74(4): 295-7.
[http://dx.doi.org/10.2340/0001555574295297 ] [PMID: 7976091]
[71]
Ippen H. Der stoffwechsel des 1, 8–dioxyanthrachinons1. Planta Med 1959; 7(04): 423-6.
[http://dx.doi.org/10.1055/s-0028-1101621]
[72]
Neill SM, Bugrein A, Coulson IH, Greaves MW. Toxicologic study of anthralin in an aqueous cream formulation. Cutis 1984; 34(6): 563-6.
[PMID: 6518819]
[73]
Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci 2012; 2(3): 129-38.
[74]
Wuis EW, Burger DM, Beelen M, Hekster YA. Stability of dithranol in creams. Pharm World Sci 1999; 21(6): 275-7.
[http://dx.doi.org/10.1023/A:1008739110004] [PMID: 10658238]
[75]
Prins M, Swinkels O, Bouwhuis S, et al. Dithranol in a cream preparation: disperse or dissolve? Skin Pharmacol and Phys 2000; 13(5): 273-9.
[http://dx.doi.org/10.1159/000029933] [PMID: 10940817]
[76]
Kirkup M, Sabroe R, Kavanagh G, et al. Twice-daily vs. once-daily inpatient dithranol for psoriasis. Clin Exp Dermatol 2002; 27(8): 695-9.
[http://dx.doi.org/10.1046/j.1365-2230.2002.01106.x ] [PMID: 12472549]
[77]
Hartman M, Prins M, Swinkels O, et al. Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol 2002; 147(3): 538-44.
[http://dx.doi.org/10.1046/j.1365-2133.2002.04920.x ] [PMID: 12207597]
[78]
McBride SR, Walker P, Reynolds NJ. Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol 2003; 149(6): 1259-65.
[http://dx.doi.org/10.1111/j.1365-2133.2003.05653.x ] [PMID: 14674905]
[79]
Yamamoto T, Nishioka K. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Skin Pharmacol Appl Skin Physiol 2003; 16(1): 50-8.
[http://dx.doi.org/10.1159/000068289] [PMID: 12566829]
[80]
Wulff-Woesten A, Ohlendorf D, Henz BM, Haas N. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol 2004; 17(2): 91-7.
[http://dx.doi.org/10.1159/000076019] [PMID: 14976386]
[81]
Kucharekova M, Lieffers L, van de Kerkhof P, van der Valk P. Dithranol irritation in psoriasis treatment: A study of 68 in patients. J Eur Acad Derm Vene 2005; 19(2): 176-9.
[http://dx.doi.org/10.1111/j.1468-3083.2005.01093.x ] [PMID: 15752286]
[82]
Myśliwiec H, Myśliwiec P, Baran A, Flisiak I. Dithranol treatment of plaque-type psoriasis increases serum TNF-like weak inducer of apoptosis (TWEAK). Adv Med Sci 2016; 61(2): 207-11.
[http://dx.doi.org/10.1016/j.advms.2016.01.001] [PMID: 26895458]

Rights & Permissions Print Cite
Article Metrics
35
© 2024 Bentham Science Publishers | Privacy Policy